BiotechTube

ARCT-032

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cystic Fibrosis

Conditions

Cystic Fibrosis, CFTR Gene Mutation

Trial Timeline

Dec 12, 2024 → Dec 1, 2025

NCT ID
NCT06747858

About ARCT-032

ARCT-032 is a phase 2 stage product being developed by Arcturus Therapeutics for Cystic Fibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06747858. Target conditions include Cystic Fibrosis, CFTR Gene Mutation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT06747858Phase 2Recruiting
NCT05712538Phase 1Completed

Competing Products

20 competing products in Cystic Fibrosis

See all competitors
ProductCompanyStageHype Score
VX-522 mRNA therapy + IVAModernaPhase 1/2
38
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
44
Enfortumab VedotinAstellas PharmaPhase 2
52
CefiderocolShionogiApproved
85
LenvatinibEisaiPhase 2
52
Lenvatinib + PembrolizumabEisaiPhase 2
52
CREONAbbVieApproved
85
Pancrelipase + PancrelipaseAbbVieApproved
85
Creon IR + Creon® (DR/GR)AbbViePhase 2
52
ABBV-CLS-628 + PlaceboAbbViePhase 2
52
Elagolix + PlaceboAbbViePhase 2
52
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222AbbViePhase 2
52
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119AbbViePhase 2
52
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
77
AZD5634 for inhalation + AZD5634 for infusionAstraZenecaPhase 1
33
Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
77
AZD1236 + PlaceboAstraZenecaPhase 2
52
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
77
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
33
AZD9668 + AZD9668 Placebo equivalentAstraZenecaPhase 2
52

Other Products from Arcturus Therapeutics

ARCT-2303 + Influenza vaccine + Influenza vaccine, adjuvantedPhase 3
69
ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine + Astra Zeneca COVID-19 vaccinePhase 2/3
57
ARCT-810Phase 2
44
ARCT-021 single dose priming + ARCT-021 two lower dose priming + ARCT-021 two higher dose priming + Placebo (two doses), priming + Randomized booster + Placebo boosterPhase 2
44
SARS-CoV-2 mRNA Vaccine ARCT-021 + TozinameranPhase 2
44